Area of research
Rheumatology · Pathology and Forensic Medicine
Research interest
Research interests include Medicine, Internal medicine, Belimumab, Hydroxychloroquine, Systemic lupus erythematosus, and Prednisolone.
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Safety and Efficacy of <scp>Long‐Term</scp> Voclosporin Treatment for Lupus Nephritis in the Phase 3 <scp>AURORA</scp> 2 Clinical Trial
Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases
Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus
2021 DORIS definition of remission in SLE: final recommendations from an international task force
<p>Practice Advisory on the Appropriate Use of NSAIDs in Primary Care</p>
A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <scp>SLE</scp>: Assessment by Drug Levels and Self‐Administered Questionnaires
Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus
Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self‐Administered Questionnaires
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G